A global phase Ill multicenter, randomized, double arm, open label trial of ASP-1929 photoimmunotherapy versus physician's choice standard of care for the treatment of patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC).

被引：7
|
作者：
Biel, Merrill A.
Gillenwater, Ann M.
Cognetti, David M.
Johnson, Jennifer Maria
Argiris, Athanassios
Tahara, Makoto
机构：
[1] Rakuten Aspyrian Inc, San Diego, CA USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA
[4] Hygeia Hosp, Maroussi, Greece
[5] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[6] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.TPS6094
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS6094
引用
收藏
页数：1
相关论文
共 44 条
  • [21] An open-label, non-randomized, multi-arm, phase II trial evaluating pembrolizumab combined with cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of the interim safety analysis.
    Sacco, Assuntina Gesualda
    Messer, Karen
    Natsuhara, Amanda
    Chen, Ruifeng
    Wong, Deborah J. L.
    Worden, Francis P.
    Adkins, Douglas
    Pittman, Emily
    Zhang, Jing
    Daniels, Gregory A.
    Gold, Kathryn A.
    Espiritu, Maechelle
    Sutton, Brian
    Cohen, Ezra E. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [22] A randomized, open-label, phase II study of afatinib versus cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Analysis of stage 2 (S2) following crossover
    Cupissol, Didier
    Seiwert, Tanguy Y.
    Fayette, Jerome
    Ehrnrooth, Eva
    Blackman, Alice Sarah
    Cong, Xiuyu Julie
    Cohen, Ezra E. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [23] Phase Ib/II, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD1 treatment naive patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
    Cohen, Ezra
    Bishnoi, Sarwan
    Laux, Douglas E.
    Wong, Deborah
    Amin, Asim
    Nabell, Lisle
    Schmidt, Emmett V.
    Xing, Biao
    Leung, Abraham C.
    Janssen, Robert
    CANCER RESEARCH, 2018, 78 (13)
  • [24] Phase Ib/II, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naive patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
    Cohen, E. E. W.
    Algazi, A.
    Laux, D.
    Wong, D. J.
    Amin, A.
    Nabell, L.
    Chisamore, M.
    Gamelin, E.
    Janssen, R.
    Bishnoi, S.
    ANNALS OF ONCOLOGY, 2018, 29 : 375 - 375
  • [25] An open-label, randomized, phase III trial of zalutumumab, a human monoclonal EGF receptor (EGFr) antibody, versus best supportive care, in patients with noncurable squamous cell carcinoma (SCCHN) of the head and neck who have failed standard platinum-based chemotherapy (ZALUTE)
    Machiels, J. H.
    Subramanian, S.
    Ruzsa, A.
    Repassy, G.
    Lifrenko, I.
    Flygare, A.
    Sorensen, P.
    Ehrnrooth, E.
    Baadsgaard, O.
    Clement, P. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [26] An open-label, non-randomized, multi-arm, phase II trial evaluating pembrolizumab combined with cetuximab in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): updated results of cohort 1 analysis
    Sacco, A. G.
    Chen, R.
    Ghosh, D.
    Worden, F.
    Wong, D. J.
    Adkins, D.
    Swiecicki, P. L.
    Chai-Ho, W.
    Pittman, E.
    Messer, K.
    Gold, K. A.
    Daniels, G.
    Sutton, B.
    Natsuhara, A.
    Cohen, E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 106 (05): : 1121 - 1122
  • [27] Afatinib versus methotrexate as second-line treatment for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) progressing on or after platinum-based therapy: LUX-Head & Neck 3 phase Ill trial.
    Guo, Ye
    Ahn, Myung-Ju
    Chan, Anthony T. C.
    Wang, Cheng-Hsu
    Kang, Jin Hyoung
    Kim, Sung-Bae
    Bello, Maximino De Guzman
    Arora, Rajendra Singh
    Zhang, Qingyuan
    He, Xiaohui
    Li, Ping
    Dechaphunkul, Arunee
    Kumar, Vijay
    Kamble, Krishna
    Li, Wei
    Kandil, Alaa
    Cohen, Ezra E. W.
    Geng, Yuan
    Zografos, Lef
    Tang, Ping Zhang
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
    Kantarjian, Hagop M.
    Thomas, Xavier G.
    Dmoszynska, Anna
    Wierzbowska, Agnieszka
    Mazur, Grzegorz
    Mayer, Jiri
    Gau, Jyh-Pyng
    Chou, Wen-Chien
    Buckstein, Rena
    Cermak, Jaroslav
    Kuo, Ching-Yuan
    Oriol, Albert
    Ravandi, Farhad
    Faderl, Stefan
    Delaunay, Jacques
    Lysak, Daniel
    Minden, Mark
    Arthur, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) : 2670 - 2677
  • [29] An open label, nonrandomized, multi-arm, phase II trial evaluating pembrolizumab combined with cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of cohort 1 interim analysis.
    Sacco, Assuntina Gesualda
    Chen, Ruifeng
    Ghosh, Debanjali
    Wong, Deborah J. L.
    Worden, Francis P.
    Adkins, Douglas
    Pittman, Emily
    Messer, Karen
    Gold, Kathryn A.
    Daniels, Gregory A.
    Swiecicki, Paul
    Sutton, Brian
    Natsuhara, Amanda
    Cohen, Ezra E. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] FRAIL-IMMUNE: A multicenter, prospective, single arm phase II of the combination of durvalumab with carboplatin and paclitaxel as firstline treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck not eligible to standard chemotherapy (GORTEC 2018-03)
    Fayette, J.
    ANNALS OF ONCOLOGY, 2019, 30
12345